Cancer: New path to improving immunotherapy
Nature Reviews Drug Discovery 17, 164 (2018).
doi:10.1038/nrd.2018.22
Author: Sarah Crunkhorn
Cancer patients with high levels of circulating myeloid-derived suppressor cells (MDSCs) have been found to respond poorly to checkpoint blockade. Accordingly, there is significant interest in therapeutically targeting these immunosuppressive innate immune cells. Writing in Cell, lead author Masoud Tavazoie and colleagues now report
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research